42052 Federal Register / Vol. 63, No. 151 /Thursday, August 6, 1998 / Notices

and private interests; and acts as the

coordinator of the total refugee and

entrant resettlement effort for ACF and

the Department.

The Discretionary Grants Unit,

responsible to the Office of the Director,

provides technical administration of

ORR discretionary grants; reviews,

certifies and/or signs all discretionary

grants; assures that all discretionary

grants awarded by ORR conform with

applicable statutes, regulations, and

policies; prepares discretionary grant

awards, ensures incorporation of

necessary grant terms and conditions,

and prepares reports and analyses on

the grantee’s use of funds; maintains

liaison and coordination with

appropriate ACF and HHS organizations

to ensure consistency between ORR

discretionary grant systems and the

Department’s grant payment systems;

and performs audit resolution activities

for ORR discretionary grant program.

B. Delete KR.20 Functions, Paragraph

C, in its entirety and replace with the

following.

C. Division of Community

Resettlement directs and manages

effective refugee resettlement through

the programmatic implementation of

grants, contracts and special initiatives

associated with national discretionary

activity. Provides management of ORR

discretionary grants; computes grantee

allocations, and monitors grantee

expenditures; analyzes financial needs

under discretionary grant programs;

provides data in support of

apportionment requests; and provides

technical assistance on discretionary

grants operations. The ORR coordinates

and provides liaison with the

Department and other federal agencies

on discretionary grants operational

issues and other activities as specified

by the Director or required by

Congressional mandate.

The Division ensures the quality of

medical screening and initial medical

treatment of refugees; collects data and

performs analyses on the changing

needs of the refugee and entrant

population; provides leadership to

identify data needs and sources,

formulates data and reporting

requirements; assists states and private

agencies on data reporting and the

resolution of reporting problems;

compiles, evaluates, and disseminates

information on the nationwide

performance and costs of refugee service

programs; responds to unanticipated

refugee and entrant arrivals or

significant increases in arrivals to

communities where adequate or

appropriate services do not exist;

strengthens the role of ethnic

community national or multi-State

organizations to promote economic

independence among refugees; provides

for English Language Training and

provides where specific needs have

been shown and recognized by the

Director for health (including mental

health) services, social services,

educational and other services.

The Division develops Repatriation

plans to make arrangements and

approve payments for temporary

assistance to certain U.S. citizens and

dependents repatriated from foreign

countries, and for the hospitalization of

certain U.S. Nationals repatriated

because of mental illness.

Dated: August 3, 1998.

Olivia A. Golden,

Assistant Secretary for Children and Families.

[FR Doc. 98–21077 Filed 8–5–98; 8:45 am]

BILLING CODE 4184–01–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

[Docket No. 98N–0320]

Agency Emergency Processing

Request Under OMB Review;

Correction

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice; correction.

SUMMARY: The Food and Drug

Administration (FDA) is correcting a

notice that appeared in the Federal

Register of June 11, 1998 (63 FR 32102).

The document announced an

opportunity for public comment on a

proposed collection of information that

has been submitted to the Office of

Management and Budget for emergency

processing under the Paperwork

Reduction Act of 1995. The notice

published with an error. This document

corrects that error.

FOR FURTHER INFORMATION CONTACT:

Margaret R. Schlosburg, Office of

Information Resources Management

(HFA–250), Food and Drug

Administration, 5600 Fishers Lane,

Rockville, MD 20857, 301–827–1223.

SUPPLEMENTARY INFORMATION: In FR Doc.

98–15484, appearing on page 32102, in

the Federal Register of Thursday, June

11, 1998, the following correction is

made:

1. On page 32103, in the second

column, beginning in the first line, ‘‘a

nutrient claim or a health claim that is

based on an authoritative statement of a

scientific body of the Federal

Government or the National Academy of

Sciences. Under these sections of the

act, a food producer that intends to use

such a claim must submit a notification

of its intention to use the claim 120 days

before it begins marketing’’ is corrected

to read ‘‘a nutrient content claim or a

health claim that is based on an

authoritative statement of certain

scientific bodies of the Federal

Government or of the National Academy

of Sciences or any of its subdivisions.

Under these sections of the act, a food

producer may use such a claim in the

labeling of an appropriate product 120

days after a complete notification of the

claim is submitted to FDA’’.

Dated: July 29, 1998.

William K. Hubbard,

Associate Commissioner for Policy

Coordination.

[FR Doc. 98–20956 Filed 8–5–98; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

Biotechnology Manufacturing

Grassroots Meeting

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice of meeting.

SUMMARY: The Food and Drug

Administration (FDA), Office of

Regulatory Affairs (ORA), Pacific

Region, and the Center for Biologics

Evaluation and Research (CBER), is

announcing the following meeting:

Biotechnology Manufacturing

Grassroots Meeting. The topic to be

discussed is mechanisms and processes

through which the agency could

potentially increase operational

efficiency in relation to both the preand post-approval inspection process;

improve communication and

cooperation among CBER, FDA field

offices, and industry representatives

associated with biotechnology

manufacturing processes; and improve

levels of consumer protection.

DATES: The meeting will be held on

Tuesday, September 15, 1998, from 8:30

a.m. to 3:30 p.m.

ADDRESSES: The meeting will be held at

the Los Angeles District Office, Food

and Drug Administration, 19900

MacArthur Blvd., suite 300, Irvine, CA

92715.

FOR FURTHER INFORMATION CONTACT:

Mark Roh (HFR–PA17), Pacific Regional

Office, Food and Drug Administration,

1301 Clay St., suite 1180–N, Oakland,

CA 94612, 510–637–3980, fax 510–637–

3977, e-mail ‘‘mroh@ora.fda.gov’’.